Renovorx Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Renovorx Inc in the second quarter 2026?
Renovorx Inc recorded a cumulative net loss of $-1 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -13.24%.

Within the Major Pharmaceutical Preparations industry Renovorx Inc achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the first quarter 2026 at no. .

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-15.62 %	-14.38 %	21.08 %	14.24 %	-
Y / Y Net Income Change	-	-	38.6 %	-	-
Net Income (TTM) in Millions	-1	-1	0	-2	-2
Return On Equity (TTM)	-13.24 %	-12.44 %	0 %	-25.21 %	-20.94 %
RNXT's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	9	11	5	8	11
Seq. Equity Change	-20.29 %	107.76 %	-32.88 %	-24.09 %	-19.12 %
Seq. Net Income Change	-	-	-	-	-

Back to RNXT Management Effectiveness >> RNXT's 5 Years Annual ROE >> Compare RNXT ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

News about Renovorx Inc Return on Equity ROE

Comparing Performance and Prospects RenovoRx Inc. in the Context of Ongoing Innovation and Revenue Challenges in Onco...

RenovoRx Inc. has recently made significant strides in the clinical landscape of oncology with the initiation of patient enrollment in its pivotal Phase III clinical trial, TIGeR-PaC, aimed at evaluating the Trans-Arterial Micro-Perfusion (TAMP) therapy platform. This groundbreaking trial, taking place at SCRI Oncology Partners, focuses on the treatment of locally advanced pancreatic cancer a condition notoriously difficult to treat and often associated with poor prognosis. The TIGeR-PaC trial is pivotal not only because of its novel approach to administering localized therapy but also due to the pressing need for innovative solutions in the battle against pancreatic cancer. Current treatment modalities have faced criticism for their systemic side effects and limited effectiveness, making localized treatment strategies, such as TAMP, a vital area of research. The aim of this trial is to assess the efficacy of TAMP in providing targeted treatment while potentially minimizing off-target effects typically associated with traditional chemotherapeutic approaches.However, while RenovoRx Inc. is advancing in its clinical pursuits, the company is also navigating a challenging financial landscape. In the second quarter of 2024, RenovoRx reported a year-on-year revenue decrease of 0%, a remarkable contrast to the general trend observed in the industry. Many of its competitors reported an average revenue increase of 5.1% during the same period, showcasing their ability to adapt and thrive in a competitive market. In light of these developments, RenovoRx’s net loss paints a cautionary picture, especially since competitors collectively recorded a 46.33% increase in income. This discrepancy underscores the importance of not only innovative clinical trials but also robust financial strategies that can support sustained growth.

RNXT Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	5	4	-3	6	15
Y / Y Equity Change	21.08 %	-	-	-59.85 %	-
Net Income in Millions	0	0	-10	-10	-6
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	0 %	0 %	-	-160.46 %	-41.2 %

Back to RNXT Management Effectiveness >> RNXT's 5 Years Annual ROE >> Compare RNXT ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RNXT's' Return on Equity at Yahoo Finance
RNXT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RNXT's Competitors
Subscribers only: Roe for Renovorx Inc 's Suppliers
Subscribers only: Return On Equity for RNXT's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:41:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.